title: Editorial: drug monitoring targets for optimising adalimumab in Crohn's disease.
authors.affiliation: Division of Gastroenterology, Hepatology & Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. swogerjm@upmc.edu.
authors.forename: J M
authors.initials: JM
authors.lastname: Swoger
authors.forename: B G
authors.initials: BG
authors.lastname: Levesque
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000906:Antibodies / Q000097:blood*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000893:Anti-Inflammatory Agents; D000906:Antibodies; D061067:Antibodies, Monoclonal, Humanized